AI assistant
Sending…
NRX Pharmaceuticals, Inc. — Director's Dealing 2021
Jun 11, 2021
34346_dirs_2021-06-10_a0b864f9-d641-43ba-bbd5-07f634f76403.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: NRX Pharmaceuticals, Inc. (NRXP)
CIK: 0001719406
Period of Report: 2021-05-24
Reporting Person: Besthof Robert (Chief Comm. & Patient Officer)
More from NRX Pharmaceuticals, Inc.
Capital/Financing Update
2026
Jun 4
Share Issue/Capital Change
2026
Jun 3
Capital/Financing Update
2026
Jun 2
Capital/Financing Update
2026
Jun 2
Interim / Quarterly Report
2026
May 15
Annual Report
2026
Mar 23
Regulatory Filings
2026
Feb 27
Annual Report
2026
Feb 23
Proxy Solicitation & Information Statement
2026
Feb 23
Regulatory Filings
2026
Feb 17